ClinicalTrials.gg

Program

ARO-INHBE

Its studies are mostly in Obesity · Fatty Liver, led by Arrowhead Pharmaceuticals.

Furthest: phase 2, since Nov 20, 20242 company-led studies, 2 open or runningNext primary completion: Oct 15, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arrowhead Pharmaceuticals22 open or runningphase 2since Nov 20, 2024Nov 20, 2024Oct 15, 2027phase 2 · NCT06700538

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 20, 2024First study: phase 2 study in ObesityFirst studyNCT06700538 · 190 enrolled · Australia, Canada, Georgia and more
  2. Jul 10, 2026Phase 2 study in Metabolic Dysfunction-Associated SteatohepatitisNCT07859813 · 252 planned

Ahead

  1. Oct 15, 2027Primary completion: phase 2 study in ObesityNCT06700538
  2. Oct 2029Primary completion: phase 2 study in Metabolic Dysfunction-Associated SteatohepatitisNCT07859813

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07859813Metabolic Dysfunction-Associated Steatohepatitis2Not yet recruitingOct 2029252
NCT06700538Obesity · Australia, Canada, Georgia and more2Active, not recruitingOct 15, 2027190

How it is read

Names in the registry

  • “ARO-INHBE”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.